- -- 29 September 2009
- immatics appoints Carsten Reinhardt as Chief Medical Officer
- -- 10 August 2009
- immatics obtains further important EP patents covering its lead product IMA901 and US patent for MUC-1 peptide
- -- 17 June 2009
- immatics biotechnologies significantly improves XPRESIDENT™ technology platform
- -- 02 March 2009
- immatics completes patient recruitment in phase II study with cancer vaccine IMA901 for renal cell cancer
- -- 26 January 2009
- immatics wins 29th German Industry's Innovation Award (Innovationspreis der deutschen Wirtschaft)
- -- 23 January 2009
- Dr. Jürgen Frisch (Chief Medical Officer) to leave immatics
immatics obtains further important EP patents covering its lead product IMA901 and US patent for MUC-1 peptide
Tübingen and Martinsried/Munich, August 10, 2009 - immatics biotechnologies GmbH today announced that the company obtained European patent protection for the composition of matter for its drug candidate IMA901. Patent no. EP1760089 will protect the set of the peptides that form the core of the pharmaceutical compositions of IMA901. The company‘s lead product is in Phase II trials in renal cancer patients. Patent EP1794190 will cover an additional MHC-Class II peptide. Both patents add to the broad IP portfolio of immatics.
Further expanding its patent portfolio covering other products, immatics has been granted US patent 7,528,224 covering a peptide encoded by the MUC-1 gene; this peptide is able to elicit an immune response against tumors overexpressing MUC-1. immatics has already obtained patent protection for this peptide in Europe.
"The first TUMAP patent owned by immatics was granted in 2004 and patent protection for peptide sequences has remained unchallenged in all major pharma markets including North America, EU, and Japan. Our IP position is therefore very strong," said Niels Emmerich, Managing Director and COO of immatics. "We will continue to expand our patent portfolio by filing patents for individual TUMAPs, our peptide-based products and our technologies in all major countries and pharma markets."
About IMA901IMA901 is an off-the-shelf cancer vaccines consisting of multiple fully synthetic tumor-associated peptides (TUMAPs), representing tumor antigens relevant for renal cell carcinoma. IMA901 is currently in a European multi-center Phase II clinical trial. The TUMAPs contained in IMA901, were identified by analyzing the HLA peptide repertoire of a large number of primary tumor tissues and were selected based on their ability to activate TUMAP-specific cytotoxic T cells and T helper cells.